Adenosquamous carcinoma of the pancreas: A distinct clinicopathologic entity

Guru Trikudanathan, Constantin A. Dasanu

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Among exocrine pancreatic tumors, adenosquamous carcinoma (ASC) is a rare, aggressive subtype with a worse prognosis and a higher potential for metastases compared to its more conventional glandular counterpart, adenocarcinoma. The disease distribution shows an approximately 1:1 male/female ratio and a median survival of circa five months. Although such features as central necrosis and hypervascularity are suggestive of pancreatic ASC, more research is necessary to identify other, more specific markers for this tumor subtype. Humoral hypercalcemia of malignancy has also been described with ASC of the pancreas, likely as a result of PTHrP production by the squamous component of the tumor. Similar to the therapeutics of pancreatic adenocarcinoma, adjuvant chemotherapy or chemoradiotherapy is currently indicated for resectable ASC of the pancreas, while gemcitabine or gemcitabine combinations are used for a more advanced disease. Both pathologic and molecular features of pancreatic ASC characterize it as a distinct subtype of pancreatic cancer. As a result, its molecular and genetic makeup could be exploited for both diagnostic and therapeutic quests in the future.

Original languageEnglish (US)
Pages (from-to)903-910
Number of pages8
JournalSouthern Medical Journal
Issue number9
StatePublished - Sep 1 2010


  • adenocarcinoma
  • adenosquamous carcinoma
  • central necrosis
  • pancreas
  • squamous cell

Fingerprint Dive into the research topics of 'Adenosquamous carcinoma of the pancreas: A distinct clinicopathologic entity'. Together they form a unique fingerprint.

Cite this